Sixth, the omission of AD pathological biomarkers, such as CSF tau/Aβ or amyloid-PET, which are currently integral to the in vivo diagnosis of AD, is a noteworthy aspect that warrants attention in future research. This evidence concerns the gene MAPT and Alzheimer disease.